The Advanced Prostate Cancer Consensus Conference
@apccc.bsky.social
APCCC facilitates discussions and debates on advanced prostate cancer diagnostic and treatment options.
Pinned
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that …
sciencedirect.com
A Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24
LINK TO ARTICLE👇👇👇👇👇👇👇👇
sciencedirect.com/science/arti...
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management
LINK TO ARTICLE👇👇👇👇👇👇👇👇
sciencedirect.com/science/arti...
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management
Association of the circulating lipid panel, PCPro, with clinical outcomes
www.annalsofoncology.org/article/S092...
post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer
www.annalsofoncology.org/article/S092...
post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304).
Enzalutamide significantly improves overall survival (OS) of patients with metastatic
hormone- sensitive prostate cancer (mHSPC). However, ∼10% of patients will die within
2 years. PCPro is a plasma l...
www.annalsofoncology.org
May 23, 2025 at 2:38 PM
Association of the circulating lipid panel, PCPro, with clinical outcomes
www.annalsofoncology.org/article/S092...
post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer
www.annalsofoncology.org/article/S092...
post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for #ProstateCancer and Mortality Risk
jamanetwork.com/journals/jam...
The field continues to evolve with the development of novel therapeutic agents, broader clinical indications, and deeper integration of nuclear imaging w/ tx
jamanetwork.com/journals/jam...
The field continues to evolve with the development of novel therapeutic agents, broader clinical indications, and deeper integration of nuclear imaging w/ tx
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
This cohort study evaluates the time necessary to accurately document a persistent prostate-specific antigen level after radical prostatectomy.
jamanetwork.com
May 22, 2025 at 8:42 AM
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for #ProstateCancer and Mortality Risk
jamanetwork.com/journals/jam...
The field continues to evolve with the development of novel therapeutic agents, broader clinical indications, and deeper integration of nuclear imaging w/ tx
jamanetwork.com/journals/jam...
The field continues to evolve with the development of novel therapeutic agents, broader clinical indications, and deeper integration of nuclear imaging w/ tx
Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence & Distant Metastases in Biochemical Recurrence of #ProstateCancer After Definitive Treatment
www.sciencedirect.com/science/arti...
Findings underscore importance of PSA stratification
www.sciencedirect.com/science/arti...
Findings underscore importance of PSA stratification
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After D...
Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) radioligands has an established role in the assessment of recurrence…
www.sciencedirect.com
May 21, 2025 at 9:10 AM
Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence & Distant Metastases in Biochemical Recurrence of #ProstateCancer After Definitive Treatment
www.sciencedirect.com/science/arti...
Findings underscore importance of PSA stratification
www.sciencedirect.com/science/arti...
Findings underscore importance of PSA stratification
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study
annalsofoncology.org/article/S092...
annalsofoncology.org/article/S092...
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.
annalsofoncology.org
May 20, 2025 at 6:16 PM
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study
annalsofoncology.org/article/S092...
annalsofoncology.org/article/S092...
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy
jamanetwork.com/journals/jam...
findings suggest that post-RP SBRT is a well-tolerated alternative to Conventionally Fractionated RT
#ProstateCancer
@silkegillessen.bsky.social 🚨
jamanetwork.com/journals/jam...
findings suggest that post-RP SBRT is a well-tolerated alternative to Conventionally Fractionated RT
#ProstateCancer
@silkegillessen.bsky.social 🚨
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy
This nonrandomized clinical trial evaluates physician-reported late toxic effects and 2-year patient-reported outcomes following post–radical prostatectomy stereotactic body radiotherapy.
jamanetwork.com
May 19, 2025 at 1:46 PM
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy
jamanetwork.com/journals/jam...
findings suggest that post-RP SBRT is a well-tolerated alternative to Conventionally Fractionated RT
#ProstateCancer
@silkegillessen.bsky.social 🚨
jamanetwork.com/journals/jam...
findings suggest that post-RP SBRT is a well-tolerated alternative to Conventionally Fractionated RT
#ProstateCancer
@silkegillessen.bsky.social 🚨
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography #ProstateCancer Molecular Imaging Standardized Evaluation (PPP2)
www.sciencedirect.com/science/arti...
PPP2 offers a robust tool for 3- and 5-year survival prediction
www.sciencedirect.com/science/arti...
PPP2 offers a robust tool for 3- and 5-year survival prediction
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International M...
We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised…
www.sciencedirect.com
May 8, 2025 at 10:15 AM
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography #ProstateCancer Molecular Imaging Standardized Evaluation (PPP2)
www.sciencedirect.com/science/arti...
PPP2 offers a robust tool for 3- and 5-year survival prediction
www.sciencedirect.com/science/arti...
PPP2 offers a robust tool for 3- and 5-year survival prediction
PEACE V–STORM: Salvage metastasis-directed therapy versus elective nodal radiotherapy☢️for oligorecurrent nodal #ProstateCancer metastases out on Lancet Oncology
www.thelancet.com/journals/lan...
Findings suggest ENRT may be a promising standard approach pending confirmation in a phase 3 trial.
www.thelancet.com/journals/lan...
Findings suggest ENRT may be a promising standard approach pending confirmation in a phase 3 trial.
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V–STORM): a phase 2, open-label, randomised controlled trial
To our knowledge, this is the first randomised trial for metachronous PET-detected
nodal recurrences comparing two local treatment approaches (MDT and ENRT) in combination
with 6 months of androgen de...
www.thelancet.com
May 7, 2025 at 8:50 AM
PEACE V–STORM: Salvage metastasis-directed therapy versus elective nodal radiotherapy☢️for oligorecurrent nodal #ProstateCancer metastases out on Lancet Oncology
www.thelancet.com/journals/lan...
Findings suggest ENRT may be a promising standard approach pending confirmation in a phase 3 trial.
www.thelancet.com/journals/lan...
Findings suggest ENRT may be a promising standard approach pending confirmation in a phase 3 trial.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
@ascocancer.bsky.social Update
ascopubs.org/doi/full/10....
Updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant #ProstateCancer
@ascocancer.bsky.social Update
ascopubs.org/doi/full/10....
Updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant #ProstateCancer
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
ASCO Guidelines provide recommendations with comprehensive review and analyses of
the relevant literature for each recommendation, following the guideline development
process as outlined in the ASCO G...
ascopubs.org
May 6, 2025 at 9:13 AM
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
@ascocancer.bsky.social Update
ascopubs.org/doi/full/10....
Updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant #ProstateCancer
@ascocancer.bsky.social Update
ascopubs.org/doi/full/10....
Updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant #ProstateCancer
Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer
aacrjournals.org/cancerres/ar...
Findings highlight promise of this integrative approach for developing non-invasive, clinically feasible diagnostic tools.
aacrjournals.org/cancerres/ar...
Findings highlight promise of this integrative approach for developing non-invasive, clinically feasible diagnostic tools.
Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer
Abstract. Early cancer diagnosis is crucial but challenging owing to the lack of reliable biomarkers that can be measured using routine clinical methods. The identification of biomarkers for early det...
aacrjournals.org
May 2, 2025 at 4:32 PM
Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer
aacrjournals.org/cancerres/ar...
Findings highlight promise of this integrative approach for developing non-invasive, clinically feasible diagnostic tools.
aacrjournals.org/cancerres/ar...
Findings highlight promise of this integrative approach for developing non-invasive, clinically feasible diagnostic tools.
Racial disparities in #ProstateCancer in the UK and the USA
nature.com/articles/s41...
paper emphasizes that addressing these inequities requires systemic change: dismantling structural racism, increasing representation in clinical research and healthcare workforce
@silkegillessen.bsky.social
nature.com/articles/s41...
paper emphasizes that addressing these inequities requires systemic change: dismantling structural racism, increasing representation in clinical research and healthcare workforce
@silkegillessen.bsky.social
April 15, 2025 at 2:46 PM
Racial disparities in #ProstateCancer in the UK and the USA
nature.com/articles/s41...
paper emphasizes that addressing these inequities requires systemic change: dismantling structural racism, increasing representation in clinical research and healthcare workforce
@silkegillessen.bsky.social
nature.com/articles/s41...
paper emphasizes that addressing these inequities requires systemic change: dismantling structural racism, increasing representation in clinical research and healthcare workforce
@silkegillessen.bsky.social
Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for #ProstateCancer
jnm.snmjournals.org/content/66/4...
These findings support its potential as a next-generation PSMA-targeted therapy with improved tumor-to-kidney uptake ratios and enhanced antitumor activity.
jnm.snmjournals.org/content/66/4...
These findings support its potential as a next-generation PSMA-targeted therapy with improved tumor-to-kidney uptake ratios and enhanced antitumor activity.
Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy
177Lu-rhPSMA-10.1 is a novel radiohybrid prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy for prostate cancer. We conducted preclinical analyses on non–tumor-bearing BALB...
jnm.snmjournals.org
April 4, 2025 at 10:08 AM
Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for #ProstateCancer
jnm.snmjournals.org/content/66/4...
These findings support its potential as a next-generation PSMA-targeted therapy with improved tumor-to-kidney uptake ratios and enhanced antitumor activity.
jnm.snmjournals.org/content/66/4...
These findings support its potential as a next-generation PSMA-targeted therapy with improved tumor-to-kidney uptake ratios and enhanced antitumor activity.
Targeting the tumour cell surface in advanced prostate cancer out on nature reviews urology
www.nature.com/articles/s41...
A deeper understanding of the dynamic nature of these targets could also inform future combination strategies.
www.nature.com/articles/s41...
A deeper understanding of the dynamic nature of these targets could also inform future combination strategies.
Targeting the tumour cell surface in advanced prostate cancer - Nature Reviews Urology
This Review provides an overview of the main targetable surface proteins in prostate cancer, defined as the surfaceome, discussing the mechanisms of action and efficacy of currently available drugs ta...
www.nature.com
April 3, 2025 at 8:00 AM
Targeting the tumour cell surface in advanced prostate cancer out on nature reviews urology
www.nature.com/articles/s41...
A deeper understanding of the dynamic nature of these targets could also inform future combination strategies.
www.nature.com/articles/s41...
A deeper understanding of the dynamic nature of these targets could also inform future combination strategies.
FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
www.fda.gov/drugs/resour...
FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI
www.fda.gov/drugs/resour...
FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI
FDA expands Pluvicto’s prostate cancer indication
On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto).
www.fda.gov
March 31, 2025 at 8:50 AM
FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
www.fda.gov/drugs/resour...
FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI
www.fda.gov/drugs/resour...
FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
jamanetwork.com/journals/jam...
These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis.
#ProstateCancer
jamanetwork.com/journals/jam...
These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis.
#ProstateCancer
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis
This randomized, noninferiority trial of biopsy-naive men compares the detection of Gleason Grade Group ≥2 prostate cancer using microultrasonography-guided and MRI fusion-guided biopsy.
jamanetwork.com
March 26, 2025 at 4:07 PM
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
jamanetwork.com/journals/jam...
These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis.
#ProstateCancer
jamanetwork.com/journals/jam...
These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis.
#ProstateCancer
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive #ProstateCancer (TITAN)
acsjournals.onlinelibrary.wiley.com/doi/full/10....
findings suggest that baseline bone metastasis count may help identify optimal candidates for apalutamide tx in mCSPC.
acsjournals.onlinelibrary.wiley.com/doi/full/10....
findings suggest that baseline bone metastasis count may help identify optimal candidates for apalutamide tx in mCSPC.
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration‐sensitive prostate cancer
In this post-hoc analysis of a phase 3 randomized controlled trial comparing apalutamide versus placebo in metastatic castration-sensitive prostate cancer, patients with two or less bone metastases h...
acsjournals.onlinelibrary.wiley.com
March 21, 2025 at 2:18 PM
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive #ProstateCancer (TITAN)
acsjournals.onlinelibrary.wiley.com/doi/full/10....
findings suggest that baseline bone metastasis count may help identify optimal candidates for apalutamide tx in mCSPC.
acsjournals.onlinelibrary.wiley.com/doi/full/10....
findings suggest that baseline bone metastasis count may help identify optimal candidates for apalutamide tx in mCSPC.
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
sciencedirect.com/science/arti...
Finds that isodose regimens, like 60 Gy in 20 fractions, are recommended as the standard for localized #ProstateCancer
sciencedirect.com/science/arti...
Finds that isodose regimens, like 60 Gy in 20 fractions, are recommended as the standard for localized #ProstateCancer
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
Trials comparing moderately hypofractionated radiotherapy (MHFRT) to conventionally-fractionated radiotherapy (CFRT) for prostate cancer have varied c…
sciencedirect.com
March 20, 2025 at 10:40 AM
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
sciencedirect.com/science/arti...
Finds that isodose regimens, like 60 Gy in 20 fractions, are recommended as the standard for localized #ProstateCancer
sciencedirect.com/science/arti...
Finds that isodose regimens, like 60 Gy in 20 fractions, are recommended as the standard for localized #ProstateCancer
Stereotactic body radiotherapy for oligoprogressive disease in androgen suppressed prostate cancer: Primary endpoint analysis of the TRAP trial
t.co/tzTr4MmoZi
TRAP Results showed a median progression-free survival (PFS) of 6.4 months, with 39% of patients maintaining PFS beyond 12 months.
t.co/tzTr4MmoZi
TRAP Results showed a median progression-free survival (PFS) of 6.4 months, with 39% of patients maintaining PFS beyond 12 months.
March 19, 2025 at 5:50 PM
Stereotactic body radiotherapy for oligoprogressive disease in androgen suppressed prostate cancer: Primary endpoint analysis of the TRAP trial
t.co/tzTr4MmoZi
TRAP Results showed a median progression-free survival (PFS) of 6.4 months, with 39% of patients maintaining PFS beyond 12 months.
t.co/tzTr4MmoZi
TRAP Results showed a median progression-free survival (PFS) of 6.4 months, with 39% of patients maintaining PFS beyond 12 months.
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for #ProstateCancer and Mortality Risk
jamanetwork.com/journals/jam...
Study suggests extending PSA assessment to at least 3 months post-RP to minimize overtreatment
@barbaramelao.bsky.social
@yukselurun.bsky.social
jamanetwork.com/journals/jam...
Study suggests extending PSA assessment to at least 3 months post-RP to minimize overtreatment
@barbaramelao.bsky.social
@yukselurun.bsky.social
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
This cohort study evaluates the time necessary to accurately document a persistent prostate-specific antigen level after radical prostatectomy.
jamanetwork.com
March 14, 2025 at 11:59 AM
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for #ProstateCancer and Mortality Risk
jamanetwork.com/journals/jam...
Study suggests extending PSA assessment to at least 3 months post-RP to minimize overtreatment
@barbaramelao.bsky.social
@yukselurun.bsky.social
jamanetwork.com/journals/jam...
Study suggests extending PSA assessment to at least 3 months post-RP to minimize overtreatment
@barbaramelao.bsky.social
@yukselurun.bsky.social
Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy
jnm.snmjournals.org/content/66/3...
The results suggest intraoperative ex vivo PET/CT could be useful for margin assessment, though further trials are needed. #ProstateCancer
jnm.snmjournals.org/content/66/3...
The results suggest intraoperative ex vivo PET/CT could be useful for margin assessment, though further trials are needed. #ProstateCancer
March 11, 2025 at 1:44 PM
Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy
jnm.snmjournals.org/content/66/3...
The results suggest intraoperative ex vivo PET/CT could be useful for margin assessment, though further trials are needed. #ProstateCancer
jnm.snmjournals.org/content/66/3...
The results suggest intraoperative ex vivo PET/CT could be useful for margin assessment, though further trials are needed. #ProstateCancer
Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment.
www.nature.com/articles/s41...
Results suggest that SBRT may be a viable option for treating omCRPC after progression compared to systemic therapy
www.nature.com/articles/s41...
Results suggest that SBRT may be a viable option for treating omCRPC after progression compared to systemic therapy
Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)...
Prostate Cancer and Prostatic Diseases - Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A...
www.nature.com
March 10, 2025 at 12:15 PM
Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment.
www.nature.com/articles/s41...
Results suggest that SBRT may be a viable option for treating omCRPC after progression compared to systemic therapy
www.nature.com/articles/s41...
Results suggest that SBRT may be a viable option for treating omCRPC after progression compared to systemic therapy
Reposted by The Advanced Prostate Cancer Consensus Conference
The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
March 7, 2025 at 1:25 PM
The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
Heterogeneity of the Treatment Effect w/ PARP Inhibitors in Metastatic Castration-resistant #ProstateCancer
sciencedirect.com/science/arti...
Overall, BRCA alterations confer the most substantial survival benefit, while minimal or no benefits were observed in patients with ATM or CHEK2 alterations
sciencedirect.com/science/arti...
Overall, BRCA alterations confer the most substantial survival benefit, while minimal or no benefits were observed in patients with ATM or CHEK2 alterations
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis
Selection of patients harboring mutations in homologous recombination repair (HRR) genes for treatment with a PARP inhibitor (PARPi) is challenging in…
sciencedirect.com
March 7, 2025 at 1:26 PM
Heterogeneity of the Treatment Effect w/ PARP Inhibitors in Metastatic Castration-resistant #ProstateCancer
sciencedirect.com/science/arti...
Overall, BRCA alterations confer the most substantial survival benefit, while minimal or no benefits were observed in patients with ATM or CHEK2 alterations
sciencedirect.com/science/arti...
Overall, BRCA alterations confer the most substantial survival benefit, while minimal or no benefits were observed in patients with ATM or CHEK2 alterations
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant #ProstateCancer
ascopubs.org/doi/pdf/10.1...
The update is based on a trial by Sartor et al., which showed improved PFS and OS in patients with PSMA-positive mCRPC after a median follow-up of 20.9 months.
ascopubs.org/doi/pdf/10.1...
The update is based on a trial by Sartor et al., which showed improved PFS and OS in patients with PSMA-positive mCRPC after a median follow-up of 20.9 months.
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A | JCO Oncology Practice
ascopubs.org
March 6, 2025 at 12:45 PM
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant #ProstateCancer
ascopubs.org/doi/pdf/10.1...
The update is based on a trial by Sartor et al., which showed improved PFS and OS in patients with PSMA-positive mCRPC after a median follow-up of 20.9 months.
ascopubs.org/doi/pdf/10.1...
The update is based on a trial by Sartor et al., which showed improved PFS and OS in patients with PSMA-positive mCRPC after a median follow-up of 20.9 months.
Reposted by The Advanced Prostate Cancer Consensus Conference
Oncology Here & Now🎙️
We interview Drs. @silkegillessen.bsky.social 🇨🇭& @aureliusomlin.bsky.social 🇨🇭and delve into Topics & evolution of Advanced #ProstateCancer Consensus Conference @apccc.bsky.social
@barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social
youtu.be/Pxzzecwqqkk?...
We interview Drs. @silkegillessen.bsky.social 🇨🇭& @aureliusomlin.bsky.social 🇨🇭and delve into Topics & evolution of Advanced #ProstateCancer Consensus Conference @apccc.bsky.social
@barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social
youtu.be/Pxzzecwqqkk?...
Oncology Here & Now Podcast: Prostate Cancer & APCCC with Drs. Silke Gillessen & Aurelius Omlin
YouTube video by OncoAlert 360
youtu.be
March 5, 2025 at 12:07 PM
Oncology Here & Now🎙️
We interview Drs. @silkegillessen.bsky.social 🇨🇭& @aureliusomlin.bsky.social 🇨🇭and delve into Topics & evolution of Advanced #ProstateCancer Consensus Conference @apccc.bsky.social
@barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social
youtu.be/Pxzzecwqqkk?...
We interview Drs. @silkegillessen.bsky.social 🇨🇭& @aureliusomlin.bsky.social 🇨🇭and delve into Topics & evolution of Advanced #ProstateCancer Consensus Conference @apccc.bsky.social
@barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social
youtu.be/Pxzzecwqqkk?...
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men W/ Suspected #ProstateCancer
jamanetwork.com/journals/jam...
Study finds men w/ negative MRI who avoided biopsy were not at increased risk of csPCa, supporting safety of an MRI-1st diagnostic approach when combined with systematic FU
jamanetwork.com/journals/jam...
Study finds men w/ negative MRI who avoided biopsy were not at increased risk of csPCa, supporting safety of an MRI-1st diagnostic approach when combined with systematic FU
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer
This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year active monitoring.
jamanetwork.com
February 25, 2025 at 11:48 AM
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men W/ Suspected #ProstateCancer
jamanetwork.com/journals/jam...
Study finds men w/ negative MRI who avoided biopsy were not at increased risk of csPCa, supporting safety of an MRI-1st diagnostic approach when combined with systematic FU
jamanetwork.com/journals/jam...
Study finds men w/ negative MRI who avoided biopsy were not at increased risk of csPCa, supporting safety of an MRI-1st diagnostic approach when combined with systematic FU